AMAG Pharmaceuticals Inc. (NASDAQ:AMAG)’s share price rose 7.7% on Thursday . The company traded as high as $24.55 and last traded at $24.02, with a volume of 1,179,051 shares. The stock had previously closed at $22.31.

AMAG has been the subject of a number of research reports. Jefferies Group decreased their price objective on AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a research report on Wednesday. Deutsche Bank AG decreased their price objective on AMAG Pharmaceuticals from $42.00 to $35.00 and set a “hold” rating for the company in a research report on Monday, May 9th. JPMorgan Chase & Co. restated a “hold” rating and set a $37.00 price objective on shares of AMAG Pharmaceuticals in a research report on Thursday, May 5th. Zacks Investment Research lowered AMAG Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, April 29th. Finally, Raymond James Financial Inc. lowered AMAG Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 4th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. AMAG Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $40.80.

The firm’s 50-day moving average price is $25.38 and its 200 day moving average price is $23.72. The company has a market cap of $798.41 million and a price-to-earnings ratio of 77.22.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings data on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. The company earned $127.40 million during the quarter, compared to the consensus estimate of $128.52 million. The company’s revenue for the quarter was up 46.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.12 EPS. On average, analysts predict that AMAG Pharmaceuticals Inc. will post $5.33 earnings per share for the current fiscal year.

Other large investors recently added to or reduced their stakes in the company. Rhumbline Advisers increased its stake in AMAG Pharmaceuticals by 10.1% in the fourth quarter. Rhumbline Advisers now owns 37,447 shares of the specialty pharmaceutical company’s stock worth $1,131,000 after buying an additional 3,420 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in AMAG Pharmaceuticals by 570.4% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 49,608 shares of the specialty pharmaceutical company’s stock worth $1,498,000 after buying an additional 42,208 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in AMAG Pharmaceuticals by 6.6% in the fourth quarter. BNP Paribas Arbitrage SA now owns 62,716 shares of the specialty pharmaceutical company’s stock worth $1,893,000 after buying an additional 3,903 shares in the last quarter. Finally, Bank of Montreal Can increased its stake in AMAG Pharmaceuticals by 2,782.5% in the fourth quarter. Bank of Montreal Can now owns 75,781 shares of the specialty pharmaceutical company’s stock worth $2,287,000 after buying an additional 73,152 shares in the last quarter.

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.